Total Payments
$72,290
2024 Payments
$383.86
Companies
76
Transactions
1,681
Medicare Patients
3,725
Medicare Billing
$797,937
Payment Breakdown by Category
Other$39,492 (54.6%)
Food & Beverage$25,695 (35.5%)
Consulting$4,800 (6.6%)
Travel$2,079 (2.9%)
Education$224.61 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $39,492 | 41 | 54.6% |
| Food and Beverage | $25,695 | 1,605 | 35.5% |
| Consulting Fee | $4,800 | 5 | 6.6% |
| Travel and Lodging | $2,079 | 21 | 2.9% |
| Education | $224.61 | 9 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $39,567 | 104 | $0 (2023) |
| Teva Pharmaceuticals USA, Inc. | $5,778 | 125 | $0 (2023) |
| Avanir Pharmaceuticals, Inc. | $4,294 | 25 | $0 (2022) |
| Biogen, Inc. | $2,207 | 163 | $0 (2023) |
| Amgen Inc. | $1,344 | 67 | $0 (2023) |
| EMD Serono, Inc. | $1,342 | 79 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $1,338 | 93 | $0 (2023) |
| ABBVIE INC. | $1,152 | 75 | $0 (2024) |
| Allergan, Inc. | $1,116 | 97 | $0 (2022) |
| Supernus Pharmaceuticals, Inc. | $908.99 | 86 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $383.86 | 8 | TG Therapeutics, Inc. ($197.51) |
| 2023 | $2,945 | 157 | EMD Serono, Inc. ($338.49) |
| 2022 | $5,469 | 308 | ABBVIE INC. ($462.18) |
| 2021 | $7,278 | 288 | GENZYME CORPORATION ($2,425) |
| 2020 | $4,886 | 218 | GENZYME CORPORATION ($1,771) |
| 2019 | $3,600 | 262 | Novartis Pharmaceuticals Corporation ($368.65) |
| 2018 | $18,096 | 225 | GENZYME CORPORATION ($15,030) |
| 2017 | $29,631 | 215 | GENZYME CORPORATION ($19,948) |
All Payment Transactions
1,681 individual payment records from CMS Open Payments — Page 1 of 68
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/26/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $123.03 | General |
| Category: Immunology | ||||||
| 07/26/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $17.01 | General |
| Category: NEUROSCIENCE | ||||||
| 05/28/2024 | ABBVIE INC. | UBRELVY (Drug), BOTOX | Food and Beverage | In-kind items and services | $15.79 | General |
| Category: NEUROSCIENCE | ||||||
| 04/23/2024 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $14.79 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 04/10/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $14.82 | General |
| Category: Neuroscience | ||||||
| 02/28/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $74.48 | General |
| Category: Immunology | ||||||
| 02/21/2024 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $109.36 | General |
| Category: Neuroscience | ||||||
| 02/21/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $14.58 | General |
| Category: Neuroscience | ||||||
| 12/11/2023 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $20.18 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 11/30/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $17.78 | General |
| Category: Neuroscience | ||||||
| 11/03/2023 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $23.12 | General |
| Category: Rare Disease | ||||||
| 07/31/2023 | SK Life Science, Inc. | — | Food and Beverage | In-kind items and services | $19.06 | General |
| 07/31/2023 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $16.20 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 07/28/2023 | EMD Serono, Inc. | MAVENCLAD (Drug) | Food and Beverage | Cash or cash equivalent | $13.72 | General |
| Category: Neurology | ||||||
| 07/27/2023 | EMD Serono, Inc. | MAVENCLAD (Drug) | Food and Beverage | Cash or cash equivalent | $24.59 | General |
| Category: Neurology | ||||||
| 07/26/2023 | Takeda Pharmaceuticals U.S.A., Inc. | — | Food and Beverage | In-kind items and services | $22.50 | General |
| 07/25/2023 | AbbVie Inc. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $14.86 | General |
| Category: NEUROSCIENCE | ||||||
| 07/24/2023 | Sumitomo Pharma America, Inc. | APTIOM (Drug) | Food and Beverage | In-kind items and services | $24.40 | General |
| Category: CNS | ||||||
| 07/21/2023 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $16.32 | General |
| Category: Immunology | ||||||
| 07/19/2023 | Neurelis, Inc. | VALTOCO (Drug) | Food and Beverage | In-kind items and services | $23.03 | General |
| Category: EPILEPSY | ||||||
| 07/19/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $15.93 | General |
| Category: Neuroscience | ||||||
| 07/18/2023 | Alexion Pharmaceuticals, Inc. | SOLIRIS (Biological) | Food and Beverage | In-kind items and services | $19.71 | General |
| Category: Rare Disease | ||||||
| 07/18/2023 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $17.65 | General |
| Category: NEUROLOGY | ||||||
| 07/12/2023 | UCB, Inc. | Briviact (Drug) | Food and Beverage | In-kind items and services | $20.00 | General |
| Category: Neurology | ||||||
| 07/12/2023 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $15.56 | General |
| Category: Neurology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 776 | 11,734 | $404,111 | $148,014 |
| 2022 | 13 | 898 | 13,315 | $500,952 | $198,587 |
| 2021 | 12 | 959 | 15,273 | $519,154 | $205,427 |
| 2020 | 12 | 1,092 | 22,582 | $646,196 | $245,909 |
Total Patients
3,725
Total Services
62,904
Medicare Billing
$797,937
Procedure Codes
54
All Medicare Procedures & Services
54 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2023 | 23 | 10,814 | $123,940 | $52,386 | 42.3% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Office | 2023 | 87 | 88 | $49,676 | $18,258 | 36.8% |
| 95912 | Nerve conduction, 11-12 studies | Office | 2023 | 90 | 94 | $54,356 | $16,938 | 31.2% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2023 | 126 | 225 | $46,235 | $15,182 | 32.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 112 | 112 | $35,990 | $12,570 | 34.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 109 | 118 | $20,109 | $7,751 | 38.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 74 | 91 | $20,479 | $7,682 | 37.5% |
| 64616 | Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | Office | 2023 | 19 | 40 | $16,412 | $5,826 | 35.5% |
| 95909 | Nerve conduction, 5-6 studies | Office | 2023 | 35 | 35 | $10,403 | $3,508 | 33.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 17 | 17 | $6,851 | $2,263 | 33.0% |
| 64612 | Injection of chemical for paralysis of nerve muscles on side of face | Office | 2023 | 13 | 28 | $9,090 | $2,193 | 24.1% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 19 | 19 | $4,158 | $1,532 | 36.8% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Facility | 2023 | 31 | 31 | $4,262 | $1,154 | 27.1% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 21 | 22 | $2,150 | $771.60 | 35.9% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2022 | 26 | 12,200 | $146,400 | $58,777 | 40.1% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Office | 2022 | 126 | 129 | $87,720 | $35,622 | 40.6% |
| 95912 | Nerve conduction, 11-12 studies | Office | 2022 | 126 | 136 | $68,272 | $25,980 | 38.1% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2022 | 153 | 303 | $53,025 | $21,726 | 41.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 116 | 116 | $37,120 | $14,282 | 38.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 74 | 74 | $29,822 | $11,937 | 40.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 75 | 89 | $18,512 | $7,370 | 39.8% |
| 64616 | Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | Office | 2022 | 17 | 48 | $14,304 | $6,651 | 46.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 35 | 40 | $11,362 | $5,101 | 44.9% |
| 64612 | Injection of chemical for paralysis of nerve muscles on side of face | Office | 2022 | 15 | 40 | $12,360 | $3,452 | 27.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 56 | 59 | $8,319 | $3,110 | 37.4% |
About Dr. Ted Barber, MD
Dr. Ted Barber, MD is a Neurology healthcare provider based in Wauseon, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/08/2005. The National Provider Identifier (NPI) number assigned to this provider is 1568460111.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ted Barber, MD has received a total of $72,290 in payments from pharmaceutical and medical device companies, with $383.86 received in 2024. These payments were reported across 1,681 transactions from 76 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($39,492).
As a Medicare-enrolled provider, Barber has provided services to 3,725 Medicare beneficiaries, totaling 62,904 services with total Medicare billing of $797,937. Data is available for 4 years (2020–2023), covering 54 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Wauseon, OH
- Active Since 07/08/2005
- Last Updated 10/29/2025
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1568460111
Products in Payments
- AUBAGIO (Drug) $35,334
- COPAXONE (Drug) $4,820
- NUEDEXTA (Drug) $4,311
- TYSABRI (Biological) $1,507
- Aimovig (Biological) $1,278
- TROKENDI XR (Drug) $786.57
- ZEPOSIA (Drug) $720.48
- Hizentra (Biological) $667.06
- UBRELVY (Drug) $663.67
- NUPLAZID (Drug) $650.75
- APTIOM (Drug) $595.72
- BOTOX (Biological) $592.46
- KESIMPTA (Drug) $573.31
- INBRIJA (Drug) $572.18
- Briviact (Drug) $522.25
- OCREVUS (Biological) $513.44
- Fycompa (Drug) $479.40
- QULIPTA (Drug) $469.48
- EMGALITY (Drug) $395.08
- VALTOCO (Drug) $382.24
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.